Last updated: April 26, 2026
Who Supplies Vancomycin Hydrochloride (API and Finished Dosage)?
Vancomycin hydrochloride is supplied through two main channels: (1) active pharmaceutical ingredient (API) under DMFs and (2) finished dosage forms (injectables and oral formulations). Supply is concentrated among specialized API manufacturers and sterile-injectable producers, with additional roles from distributors and contract manufacturers.
Which companies supply vancomycin hydrochloride as an API?
Vancomycin API supply is typically documented via regulatory dossiers (DMFs) and commercialization agreements tied to specific strengths and salt forms (vancomycin hydrochloride). Major global suppliers include:
- Sichuan Mingxin Pharmaceutical Co., Ltd. (China)
- Cangzhou Dahua Pharmaceutical Co., Ltd. (China)
- Jiangsu Hengrui Medicine Co., Ltd. (China)
- Aurobindo Pharma (API operations in India; supplier for multiple sterile and non-sterile products)
- Glenmark Pharmaceuticals (API operations; supplier footprint across antibiotics)
- Dr. Reddy’s Laboratories (API operations; supplier footprint across injectables)
- Cipla (API and product supply footprint; antibiotics)
- Pfizer (historical and legacy supply footprint; product and manufacturing network)
Note on salt form: Market-facing suppliers often list “vancomycin hydrochloride” or “vancomycin hydrochloride sterile” for injectable API-grade or directly for finished sterile vials.
Which companies supply vancomycin hydrochloride finished products (injectable vials)?
Finished vancomycin hydrochloride products are supplied by sterile-injectable manufacturers under brand or generic labels. In practice, supply involves large sterile manufacturing networks and multiple ANDA holders depending on market and exclusivity periods.
Key suppliers and product makers include:
- Pfizer (US/EU product supply via legacy manufacturing network)
- Sandoz (sterile and generic supply)
- Hospira (legacy sterile network; Pfizer-owned historically)
- Mylan / Viatris (generic injectable supply)
- Teva Pharmaceuticals (generic injectable supply)
- Dr. Reddy’s Laboratories (injectable supply footprint)
- Sagent Pharmaceuticals / Lannet / Hikma (generic injectable supply footprint depending on market)
- **Fresenius Kabi (sterile injectable supply footprint in antibiotics)
What supplier categories matter for sourcing decisions?
A procurement strategy for vancomycin hydrochloride typically depends on whether the buyer needs API or finished sterile supply.
| Buyer need |
Typical supplier type |
What they provide |
| API |
DMF-holding API manufacturer |
vancomycin hydrochloride API, CoA, compliance documentation |
| Finished injectable |
Sterile injectables manufacturer |
labeled vials (sterile, lyophilized/powder or solution depending on market) |
| Back-up supply |
Multiple ANDA holders and distributors |
alternate SKUs, channel inventory coverage |
| Speed-to-market |
Contract manufacturing network |
risk-managed fill-finish and packaging capacity |
What quality and compliance expectations apply to vancomycin hydrochloride supply?
Procurement of vancomycin hydrochloride API and finished sterile products usually requires compliance with pharmacopeia specifications and current good manufacturing practice (cGMP).
Key regulatory anchors:
- FDA cGMP for drug manufacturing and quality systems (21 CFR Parts 210 and 211 for finished pharmaceuticals).
- ICH quality framework for stability, impurity profiling, and validation practices.
- Pharmacopeia monographs for vancomycin hydrochloride identity, assay, impurities, and related substances (commonly USP, with EP for European dossiers).
From a supplier due diligence standpoint, buyers usually validate:
- Sterility strategy for injectable products (as applicable)
- Endotoxin testing and microbial limits (finished vials)
- Stability commitments and retest periods (API)
- Impurity profiles and change notification history (API and finished goods)
- Supply continuity and deviation history
How suppliers position for global distribution
Vancomycin supply is frequently staged through:
- API manufacturers producing vancomycin hydrochloride under DMFs.
- Finished dose makers performing sterile manufacturing and packaging.
- Distributors and wholesale channels covering region-by-region inventory.
This structure is designed to reduce single-point failure risk because vancomycin has cyclical demand surges driven by hospital utilization.
Supplier shortlists used in procurement tend to look like this
Below is a procurement-oriented view of where buyers typically allocate vendor assessments.
API vendor shortlist (examples of known active manufacturers in the market):
- Sichuan Mingxin Pharmaceutical Co., Ltd.
- Cangzhou Dahua Pharmaceutical Co., Ltd.
- Jiangsu Hengrui Medicine Co., Ltd.
Finished injectable vendor shortlist (region-dependent):
- Pfizer
- Sandoz
- Teva Pharmaceuticals
- Viatris / Mylan
- Dr. Reddy’s Laboratories
- Fresenius Kabi
What should a buyer verify in RFQs (vendor questions that map to supply risk)?
Procurement teams typically require evidence of:
- DMF/registration status for the API salt form (vancomycin hydrochloride)
- Batch release documentation (CoA format, test methods, release limits)
- Change control history for manufacturing process, synthesis route, and analytical methods
- Stability packages aligned to their shelf-life requirements
- Sterile manufacturing controls (for vials) including sterility assurance and endotoxin limits
- Logistics readiness (cold-chain not usually required, but shipper qualification and packaging integrity are)
- Lead time and safety stock plan (especially where shortages have occurred)
Key Takeaways
- Vancomycin hydrochloride supply splits into API manufacturers and sterile injectable finished-product makers, with distributors completing the chain.
- The market includes multiple global players across China-based API production and large generic/sterile firms for injectable vials.
- Sourcing diligence should center on DMF status, salt form control, impurity and stability packages, and sterile quality systems for vials.
FAQs
-
Is vancomycin hydrochloride supplied as API and finished vials by the same companies?
Often no. API vendors typically sell API under DMFs, while finished injectable production is handled by sterile injectables manufacturers, sometimes different companies.
-
Which part of the value chain drives regulatory filings for vancomycin hydrochloride?
API vendors drive DMF filings for the API; finished-product makers drive ANDA filings, labeling, and sterile product quality submissions.
-
What documents matter most when qualifying a vancomycin hydrochloride API source?
CoA, impurity specifications, stability reports, change control summaries, and DMF-aligned manufacturing evidence.
-
What quality systems are most critical for vancomycin hydrochloride injection?
Sterile manufacturing controls, endotoxin limits, microbial limits, sterility assurance, and batch release testing under cGMP.
-
How do procurement teams reduce shortage risk for vancomycin hydrochloride?
By dual-sourcing across multiple finished-product and API suppliers and maintaining safety stock through distributor and hospital purchasing channels.
References
[1] U.S. Food and Drug Administration. “Current Good Manufacturing Practice (CGMP).” FDA, 2024. https://www.fda.gov/drugs/current-good-manufacturing-practice-cgmp-drugs
[2] U.S. Food and Drug Administration. “Drug Master Files (DMFs).” FDA, 2024. https://www.fda.gov/drugs/drug-master-files-dmfs
[3] ICH. “ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients.” International Council for Harmonisation, 2000 (latest consolidated version). https://www.ich.org/
[4] European Pharmacopoeia. “Vancomycin Hydrochloride” monograph (as applicable by edition). Council of Europe. https://www.edqm.eu/
[5] United States Pharmacopeia (USP). “Vancomycin Hydrochloride” monograph (as applicable by edition). USP. https://www.uspnf.com/
